While clinical trials are ongoing, a study published in Alzheimers & Dementia in October 2024 found that people with Type 2 diabetes who used semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) had a lower risk of a first-time diagnosis of Alzheimers disease, compared to people who used insulin, other GLP-1s, or other diabetes medicines
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) not yet licensed by the MHRA or EMA as of 2024
This means body composition, not just total weight, influences how tirzepatide distributes and persists
Molecular size Tirzepatide is a large peptide molecule
Potential Benefits As NAD+ is present in every cell and involved in almost every process, the potential benefits of NAD+ Therapy (and supplementation with NAD+ precursors) are wide-ranging